EKSO Relative Valuation
EKSO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EKSO is overvalued; if below, it's undervalued.
Historical Valuation
Ekso Bionics Holdings Inc (EKSO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.12. The fair price of Ekso Bionics Holdings Inc (EKSO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：4.42
Fair
-3.63
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Ekso Bionics Holdings Inc. (EKSO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.54. The thresholds are as follows: Strongly Undervalued below -5.34, Undervalued between -5.34 and -2.94, Fairly Valued between 1.86 and -2.94, Overvalued between 1.86 and 4.27, and Strongly Overvalued above 4.27. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-4.00
EV/EBIT
Ekso Bionics Holdings Inc. (EKSO) has a current EV/EBIT of -4.00. The 5-year average EV/EBIT is -1.50. The thresholds are as follows: Strongly Undervalued below -5.31, Undervalued between -5.31 and -3.40, Fairly Valued between 0.40 and -3.40, Overvalued between 0.40 and 2.31, and Strongly Overvalued above 2.31. The current Forward EV/EBIT of -4.00 falls within the Undervalued range.
0.65
PS
Ekso Bionics Holdings Inc. (EKSO) has a current PS of 0.65. The 5-year average PS is 2.07. The thresholds are as follows: Strongly Undervalued below -2.32, Undervalued between -2.32 and -0.13, Fairly Valued between 4.27 and -0.13, Overvalued between 4.27 and 6.47, and Strongly Overvalued above 6.47. The current Forward PS of 0.65 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Ekso Bionics Holdings Inc. (EKSO) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.24. The thresholds are as follows: Strongly Undervalued below -3.02, Undervalued between -3.02 and -1.63, Fairly Valued between 1.15 and -1.63, Overvalued between 1.15 and 2.54, and Strongly Overvalued above 2.54. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Ekso Bionics Holdings Inc. (EKSO) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.20. The thresholds are as follows: Strongly Undervalued below -2.99, Undervalued between -2.99 and -1.59, Fairly Valued between 1.20 and -1.59, Overvalued between 1.20 and 2.59, and Strongly Overvalued above 2.59. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Ekso Bionics Holdings Inc (EKSO) has a current Price-to-Book (P/B) ratio of 1.20. Compared to its 3-year average P/B ratio of 1.18 , the current P/B ratio is approximately 1.29% higher. Relative to its 5-year average P/B ratio of 1.90, the current P/B ratio is about -36.96% higher. Ekso Bionics Holdings Inc (EKSO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -73.84%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -57.29% , the current FCF yield is about -100.00% lower.
1.10
P/B
Median3y
1.18
Median5y
1.90
-59.92
FCF Yield
Median3y
-73.84
Median5y
-57.29
Competitors Valuation Multiple
The average P/S ratio for EKSO's competitors is 0.00, providing a benchmark for relative valuation. Ekso Bionics Holdings Inc Corp (EKSO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 2.37%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of EKSO decreased by 55.52% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 4.13M to 4.23M.
The secondary factor is the P/E Change, contributed -24.89%to the performance.
Overall, the performance of EKSO in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Ekso Bionics Holdings Inc (EKSO) currently overvalued or undervalued?
What is Ekso Bionics Holdings Inc (EKSO) fair value?
How does EKSO's valuation metrics compare to the industry average?
What is the current P/B ratio for Ekso Bionics Holdings Inc (EKSO) as of Dec 05 2025?
What is the current FCF Yield for Ekso Bionics Holdings Inc (EKSO) as of Dec 05 2025?
What is the current Forward P/E ratio for Ekso Bionics Holdings Inc (EKSO) as of Dec 05 2025?